Journal Title：Expert Review Of Anticancer Therapy

Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.

Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.

Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:

Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results

Article Highlights – an executive summary of the author’s most critical points.

《抗癌治療專家評論》（ISSN 1473-7140）對癌癥治療的主要趨勢提供專家評估和評論，并強調(diào)新的治療和診斷方法的表現(xiàn)。

內(nèi)容包括腫瘤管理、新型藥物、抗癌劑和化療、生物治療、癌癥疫苗、治療指征、生物標(biāo)志物和診斷以及治療指南。所有文章都經(jīng)過嚴(yán)格的同行評審，該期刊對癌癥治療的決策做出了重要貢獻。

每篇評論的全面報道都由獨特的專家評論格式補充，并包括以下部分：

專家意見 - 對文章中呈現(xiàn)的數(shù)據(jù)的個人看法，對未來可能重要的發(fā)展進行討論，以及隨著進一步研究產(chǎn)生更詳細的結(jié)果，可能變得令人興奮的研究途徑

文章重點 - 作者最關(guān)鍵觀點的執(zhí)行摘要。

Expert Review Of Anticancer Therapy創(chuàng)刊于2001年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋醫(yī)學(xué) - 腫瘤學(xué)全領(lǐng)域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認(rèn)可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 偏慢,4-8周 ，影響因子指數(shù)2.9，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。